|
1
|
Committee for Scientific Affairs, The
Japanese Association for Thoracic Surgery, ; Masuda M, Kuwano H,
Okumura M, Amano J, Arai H, Endo S, Doki Y, Kobayashi J, Motomura
N, Nishida H, et al: Thoracic and cardiovascular surgery in Japan
during 2012: Annual report by The Japanese Association for thoracic
surgery. Gen Thorac Cardiovasc Surg. 62:734–764. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Herbst RS and Shin DM: Monoclonal
antibodies to target epidermal growth factor receptor-positive
tumors: A new paradigm for cancer therapy. Cancer. 94:1593–1611.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morita S, Okamoto I, Kobayashi K, Yamazaki
K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T,
et al: Combined survival analysis of prospective clinical trials of
gefitinib for non-small cell lung cancer with EGFR mutations. Clin
Cancer Res. 15:4493–4498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mazières J, Peters S, Lepage B, Cortot AB,
Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban
T, et al: Lung cancer that harbors an HER2 mutation: Epidemiologic
characteristics and therapeutic perspectives. J Clin Oncol.
31:1997–2003. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang SE, Narasanna A, Perez-Torres M,
Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK and
Arteaga CL: HER2 kinase domain mutation results in constitutive
phosphorylation and activation of HER2 and EGFR and resistance to
EGFR tyrosine kinase inhibitors. Cancer Cell. 10:25–38. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Onitsuka T, Uramoto H, Nose N, Takenoyama
M, Hanagiri T, Sugio K and Yasumoto K: Acquired resistance to
gefitinib: The contribution of mechanisms other than the T790M,
MET, and HGF status. Lung Cancer. 68:198–203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yano S, Wang W, Li Q, Matsumoto K,
Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka
Y, et al: Hepatocyte growth factor induces gefitinib resistance of
lung adenocarcinoma with epidermal growth factor
receptor-activating mutations. Cancer Res. 68:9479–9487. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yun CH, Mengwasser KE, Toms AV, Woo MS,
Greulich H, Wong KK, Meyerson M and Eck MJ: The T790M mutation in
EGFR kinase causes drug resistance by increasing the affinity for
ATP. Proc Natl Acad Sci USA. 105:2070–2075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wright S and Ddbzhansky T: Genetics of
natural populations Xii. Experimental reproduction of some of the
changes caused by natural selection in certain populations of
drosophila-pseudoobscura. Genetics. 31:125–156. 1945.
|
|
11
|
Bryant HE, Schultz N, Thomas HD, Parker
KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Farmer H, McCabe N, Lord CJ, Tutt ANJ,
Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I,
Knights C, et al: : Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature. 434:917–921. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
McLornan DP, List A and Mufti GJ: Applying
synthetic lethality for the selective targeting of cancer. N Engl J
Med. 371:1725–1735. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Corcoran RB, Cheng KA, Hata AN, Faber AC,
Ebi H, Coffee EM, Greninger P, Brown RD, Godfrey JT, Cohoon TJ, et
al: Synthetic lethal interaction of combined BCL-XL and MEK
inhibition promotes tumor regressions in KRAS mutant cancer models.
Cancer Cell. 23:121–128. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lamba S, Russo M, Sun C, Lazzari L,
Cancelliere C, Grernrum W, Lieftink C, Bernards R, Di Nicolantonio
F and Bardelli A: RAF suppression synergizes with MEK inhibition in
KRAS mutant cancer cells. Cell Rep. 8:1475–1483. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ellis C, Moran M, McCormick F and Pawson
T: Phosphorylation of GAP and GAP-associated proteins by
transforming and mitogenic tyrosine kinases. Nature. 343:377–381.
1990. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Settleman J, Narasimhan V, Foster LC and
Weinberg RA: Molecular cloning of cDNAs encoding the GAP-associated
protein p190: Implications for a signaling pathway from ras to the
nucleus. Cell. 69:539–549. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brouns MR, Matheson SF and Settleman J:
p190 RhoGAP is the principal Src substrate in brain and regulates
axon outgrowth, guidance and fasciculation. Nat Cell Biol.
3:361–367. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang JH, Gill S, Settleman J and Parsons
SJ: c-Src regulates the simultaneous rearrangement of actin
cytoskeleton, pl90RhoGAP, and pl20RasGAP following epidermal growth
factor stimulation. J Cell Biol. 130:355–368. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kusama T, Mukai M, Endo H, Ishikawa O,
Tatsuta M, Nakamura H and Inoue M: Inactivation of Rho GTPases by
p190 RhoGAP reduces human pancreatic cancer cell invasion and
metastasis. Cancer Sci. 97:848–853. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shen CH, Chen HY, Lin MS, Li FY, Chang CC,
Kuo ML, Settleman J and Chen RH: Breast tumor kinase phosphorylates
p190RhoGAP to regulate rho and ras and promote breast carcinoma
growth, migration, and invasion. Cancer Res. 68:7779–7787. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo A, Villén J, Kornhauser J, Lee KA,
Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R,
et al: Signaling networks assembled by oncogenic EGFR and c-Met.
Proc Natl Acad Sci USA. 105:692–697. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rikova K, Guo A, Zeng Q, Possemato A, Yu
J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al: Global survey
of phosphotyrosine signaling identifies oncogenic kinases in lung
cancer. Cell. 131:1190–1203. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Notsuda H, Sakurada A, Endo C, Okada Y,
Horii A, Shima H and Kondo T: p190A RhoGAP is involved in EGFR
pathways and promotes proliferation, invasion and migration in lung
adenocarcinoma cells. Int J Oncol. 43:1569–1577. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu H, Ding WJ, Wu R, Weng QJ, Lou JS, Jin
RJ, Lu W, Yang B and He QJ: Synergistic anti-cancer activity by the
combination of TRAIL/APO-2L and celastrol. Cancer Invest. 28:23–32.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scaltriti M and Baselga J: The epidermal
growth factor receptor pathway: A model for targeted therapy. Clin.
Cancer Res. 12:5268–5272. 2006.
|
|
29
|
Chen JC, Zhuang S, Nguyen TH, Boss GR and
Pilz RB: Oncogenic Ras leads to Rho activation by activating the
mitogen-activated protein kinase pathway and decreasing
Rho-GTPase-activating protein activity. J Biol Chem. 278:2807–2818.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pullikuth AK and Catling AD: Extracellular
signal-regulated kinase promotes Rho-dependent focal adhesion
formation by suppressing p190A RhoGAP. Mol Cell Biol. 30:3233–3248.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Appleman LJ: MET signaling pathway: A
rational target for cancer therapy. J Clin Oncol. 29:4837–4838.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Moasser MM: The oncogene HER2: Its
signaling and transforming functions and its role in human cancer
pathogenesis. Oncogene. 26:6469–6487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nakamura T, Sakai K, Nakamura T and
Matsumoto K: Hepatocyte growth factor twenty years on: Much more
than a growth factor. J Gastroenterol Hepatol. 26 Suppl
1:S188–S202. 2011. View Article : Google Scholar
|
|
34
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal
transducer and activator of transcription-3, inflammation, and
cancer: How intimate is the relationship? Ann NY Acad Sci.
1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Akira S, Nishio Y, Inoue M, Wang XJ, Wei
S, Matsusaka T, Yoshida K, Sudo T, Naruto M and Kishimoto T:
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3
p91-related transcription factor involved in the gp130-mediated
signaling pathway. Cell. 77:63–71. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhong Z, Wen Z and Darnell JE Jr: Stat3: A
STAT family member activated by tyrosine phosphorylation in
response to epidermal growth factor and interleukin-6. Science.
264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dauer DJ, Ferraro B, Song L, Yu B, Mora L,
Buettner R, Enkemann S, Jove R and Haura EB: Stat3 regulates genes
common to both wound healing and cancer. Oncogene. 24:3397–3408.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Turkson J and Jove R: STAT proteins: Novel
molecular targets for cancer drug discovery. Oncogene.
19:6613–6626. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li CJ, Li YC, Zhang DR and Pan JH: Signal
transducers and activators of transcription 3 function in lung
cancer. J Cancer Res Ther. 9 Suppl 2:S67–S73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang
J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3
signaling pathway in cancer: Role of synthetic and natural
inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
|
|
41
|
Song L, Rawal B, Nemeth JA and Haura EB:
JAK1 activates STAT3 activity in non-small-cell lung cancer cells
and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
Mol Cancer Ther. 10:481–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bendell JC, Hong DS, Burris HA III, Naing
A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP and Kurzrock
R: Phase 1, open-label, dose-escalation, and pharmacokinetic study
of STAT3 inhibitor OPB-31121 in subjects with advanced solid
tumors. Cancer Chemother Pharmacol. 74:125–130. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Verstovsek S, Mesa RA, Gotlib J, Levy RS,
Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver
RT, et al: A double-blind, placebo-controlled trial of ruxolitinib
for myelofibrosis. N Engl J Med. 366:799–807. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jain N, Zhang T, Kee WH, Li W and Cao X:
Protein kinase C δ associates with and phosphorylates Stat3 in an
interleukin-6-dependent manner. J Biol Chem. 274:24392–24400. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Olejniczak M, Galka P and Krzyzosiak WJ:
Sequence-non-specific effects of RNA interference triggers and
microRNA regulators. Nucleic Acids Res. 38:1–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Johnson FM, Bekele BN, Feng L, Wistuba I,
Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR,
et al: Phase II study of dasatinib in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 28:4609–4615. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chircop M: Rho GTPases as regulators of
mitosis and cytokinesis in mammalian cells. Small GTPases.
5:e297702014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cocchiola R, Grillo C, Altieri F,
Chichiarelli S, Turano C and Eufemi M: Upregulation of TPX2 by
STAT3: Identification of a novel STAT3 binding site. PLoS One.
9:e1130962014. View Article : Google Scholar : PubMed/NCBI
|
